HIV-associated lipodystrophy: Pathogenesis, prognosis, treatment, and controversies

Annual Review of Medicine

Volumn 55, Issue , 2004, Pages 303-317

  Koutkia, Polyxeni ^a   Grinspoon, Steven ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

HIV; Insulin resistance; Lipodystrophy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATORVASTATIN; EFAVIRENZ; FENOFIBRATE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; METFORMIN; NEVIRAPINE; PRAVASTATIN; PROTEINASE INHIBITOR; RECOMBINANT GROWTH HORMONE; RITONAVIR; ROSIGLITAZONE; SAQUINAVIR; SIMVASTATIN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIET; DRUG WITHDRAWAL; DYSLIPIDEMIA; ESTHETIC SURGERY; FAMILY HISTORY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; INSULINEMIA; LACTIC ACIDOSIS; LIFESTYLE; LIPOSUCTION; METABOLIC DISORDER; PATHOGENESIS; PHYSICAL ACTIVITY; PLASTIC SURGERY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR;

HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; PROGNOSIS;

EID: 1542299096     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.55.091902.104412     Document Type: Review

References (76)

1. Hengel RL, Watts NB, Lennox JL. 1997. Benign symmetric lipomatosis associated with protease inhibitors. Lancet 350: 1596
2. Carr A, Cooper DA. 1998. Lipodystrophy associated with an HIV-protease inhibitor. N. Engl. J. Med. 339:1296
3. Lo JC, Mulligan K, Tai VW, et al. 1998. "Buffalo hump" in men with HIV-1 infection. Lancet 351:871-75
4. Hadigan C, Meigs JB, Corcoran C, et al. 2001. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin. Infect. Dis. 32:130-39
5. Kotler DP, Rosenbaum K, Wang J, et al. 1999. Studies of body composition and fat distribution in HIV-infected and control subjects. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20:228-37
6. Panse I, Vasseur E, Raffin-Sanson ML, et al. 2000. Lipodystrophy associated with protease inhibitors. Br. J. Dermatol. 142: 496-500
7. Kasper T, Arboleda C, Halpern M. 2000. The impact of patient perceptions of body shape changes and metabolic abnormalities on antiretroviral therapy. Presented at XIII Int. AIDS Conf., Durban, South Africa, Jul. 9-14
8. Hadigan C, Corcoran C, Stanley T, et al. 2000. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J. Clin. Endocrinol. Metab. 85:35-41
9. Mallal SA, John M, Moore CB, et al. 2000. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14:1309-16
10. Saint-Marc T, Partisani M, Poizot-Martin I, et al. 1999. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13:1659-67
11. Carr A, Samaras K, Burton S, et al. 1998. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51-58
12. Meininger G, Hadigan C, Rietschel P, et al. 2002. Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. Am. J. Clin. Nutr. 76:460-65
13. Noor MA, Seneviratne T, Aweeka FT, et al. 2002. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 16:F1-8
14. Murata H, Hruz PW, Mueckler M. 2000. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem. 275:20251-54
15. Hadigan C, Meigs JB, Rabe J, et al. 2001. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J. Clin. Endocrinol. Metab. 86:939-43
16. Zhang B, MacNaul K, Szalkowski D, et al. 1999. Inhibition of adipocyte differentiation by HIV protease inhibitors. J. Clin. Endocrinol. Metab. 84:4274-77
17. Domingo P, Matias-Guiu X, Pujol RM, et al. 1999. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 13:2261-67
18. Mulligan K, Grunfeld C, Tai VW, et al. 2000. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J. Acquir. Immune Defic. Syndr. 23:35-43
19. Yanovski JA, Miller KD, Kino T, et al. 1999. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J. Clin. Endocrinol. Metab. 84:1925-31
20. Miller KK, Daly PA, Sentochnik D, et al. 1998. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 27:68-72
21. Bujalska IJ, Kumar S, Stewart PM. 1997. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 349:1210-13
22. Rebuffe-Scrive M, Bronnegard M, Nilsson A, et al. 1990. Steroid hormone receptors in human adipose tissues. J. Clin. Endocrinol. Metab. 71:1215-19
23. Carr A, Samaras K, Chisholm DJ, Cooper DA. 1998. Pathogenesis of HIV-1-protease-inhibitor-associated peripheral lipodystrophy, hyperlipidemia and insulin resistance. Lancet 352:1881-83
24. Li E, Norris AW. 1996. Structure/function of cytoplasmic vitamin A-binding proteins. Annu. Rev. Nutr. 16:205-34
25. Tontonoz P, Hu E, Spiegelman BM. 1995. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr. Opin. Genet. Dev. 5:571-76
26. Stevens GJ, Chen M, Grecko R, Lankford A, et al. 1999. Investigations into proposed mechanisms of HIV-associated peripheral lipodystrophy, hyperlipidemia and insulin resistance. Presented at Int. Workshop Adverse Drug Reactions and Lipodystrophy in HIV, 1st, San Diego, CA, Jun. 26-29
27. Lenhard JM, Furfine ES, Jain RG, et al. 2000. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral. Res. 47:121-29
28. Rohlmann A, Gotthardt M, Hammer RE, et al. 1998. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J. Clin. Invest. 101:689-95
29. Martinez E, Gatell J. 1998. Metabolic abnormalities and use of HIV-1 protease inhibitors. Lancet 352:821-22
30. Stricker RB, Goldberg B. 1998. Fat accumulation and HIV-1 protease inhibitors. Lancet 352:1392
31. Roth VR, Kravcik S, Angel JB. 1998. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin. Infect. Dis. 27:65-67
32. Domingo P, Matias-Guiu X, Pujol RM, et al. 2001. Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy. J. Infect. Dis. 184:1197-201
33. Bastard JP, Caron M, Vidal H, et al. 2002. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359:1026-31
34. Speckman RA, Garg A, Du F, et al. 2000. Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C. Am. J. Hum. Genet. 66:1192-98
35. Suzawa M, Takada I, Yanagisawa J, et al. 2003. Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade. Nat. Cell. Biol. 5:224-30
36. Lichtenstein KA, Ward DJ, Moorman AC, et al. 2001. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15:1389-98
37. Mynarcik DC, McNurlan MA, Steigbigel RT, et al. 2000. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J. Acquir. Immune Defic. Syndr. 25:312-21
38. Grunfeld C, Pang M, Doerrler W. 1991. Circulating interferon alpha levels and hyper-triglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. 90:154-62
39. Grunfeld C, Feingold KR. 1992. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N. Engl. J. Med. 327:329-37
40. Purnell JQ, Zambon A, Knopp RH, et al. 2000. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14:51-57
41. Ranganathan S, Kern PA. 2002. The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes. J. Endocrinol. 172:155-62
42. Liang JS, Distler O, Cooper DA, et al. 2001. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat. Med. 7:1327-31
43. Hadigan C, Rabe J, Grinspoon S. 2002. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J. Clin. Endocrinol. Metab. 87:4611-15
44. Sattler FR, Qian D, Louie S, et al. 2001. Elevated blood pressure in subjects with lipodystrophy. AIDS 15:2001-10
45. Hadigan C, Borgonha S, Rabe J, et al. 2002. Increased rates of lipolysis among HIV-infected men receiving highly active antiretroviral therapy. Metabolism 51:1143-47
46. Meininger G, Hadigan C, Laposata M, et al. 2002. Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metabolism 51:260-66
47. Hadigan C, Rabe J, Meininger G, et al. 2003. Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution. Am. J. Clin. Nutr. 77:490-94
48. Hadigan C, Meigs JB, Wilson PWF, et al. 2003. Prediction of coronary heart disease in HIV-infected patients with fat redistribution. Clin. Infect. Dis. 36:909-16
49. Henry K, Melroe H, Huebsch J, et al. 1998. Severe premature coronary artery disease with protease inhibitors. Lancet 351:1328
50. Mary-Krause M, Cotte L, Partisani M, et al. 2001. Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected men. Presented at Conf. Retroviruses and Opportunistic Infections, 8th, Chicago, IL, Feb. 4-8
51. Klein D, Hurley LB, Quesenberry CP Jr, et al. 2002. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J. Acquir. Immune Defic. Syndr. 30:471-77
52. Bozzette SA, Ake CF, Tam HK, et al. 2003. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N. Engl. J. Med. 348:702-10
53. Meigs JB, Mittleman MA, Nathan DM, et al. 2000. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 283: 221-28
54. Johansson L, Jansson JH, Boman K, et al. 2000. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 31:26-32
55. Dressman J, Kincer J, Matveev SV, et al. 2003. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J. Clin. Invest. 111:389-97
56. Maggi P, Serio G, Epifani G, et al. 2000. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 14:F123-28
57. Zhong DS, Lu XH, Conklin BS, et al. 2002. HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 22:1560-66
58. Stein JH, Klein MA, Bellehumeur JL, et al. 2001. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104:257-62
59. Roubenoff R, Weiss L, McDermott A, et al. 1999. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 13:1373-75
60. Jones SP, Doran DA, Leatt PB, et al. 2001. Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. AIDS 15:2049-51
61. Yarasheski KE, Tebas P, Stanerson B, et al. 2001. Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J. Appl. Physiol. 90:133-38
62. Hadigan C, Jeste S, Anderson EJ, et al. 2001. Modifiable dietary habits and their relation to metabolic abnormalities in men and women with human immunodeficiency virus infection and fat redistribution. Clin. Infect. Dis. 33:710-17
63. Martinez E, Conget I, Lozano L, et al. 1999. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 13:805-10
64. Barreiro P, Soriano V, Blanco F, et al. 2000. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 14:807-12
65. Lafon E, Landman R, Quertainmont M, et al. 2000. LIPSTOP study: evolution of clinical lipodystrophy (LD) blood lipids, visceral (VAT) and subcutaneous (SAT) adipose tissue after switching from protease inhibitor (PI) to efavirenx (EFV) in HIV-1 infected patients. Presented at Int. AIDS Conf. Durban, South Africa, XIII, Jul. 9-14
66. Hatano H, Miller KD, Yoder CP, et al. 2000. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS 14:1935-42
67. Henry K, Melroe H, Huebesch J, et al. 1998. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 352:1031-32
68. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. 2002. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16:569-77
69. Hadigan C, Corcoran C, Basgoz N, et al. 2000. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 284:472-77
70. Arioglu E, Duncan-Morin J, Sebring N, et al. 2000. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann. Intern. Med. 133:263-74
71. Gelato MC, Mynarcik DC, Quick JL, et al. 2002. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J. Acquir. Immune Defic. Syndr. 31: 163-70
72. Yki-Jarvinen H, Sutinen J, Silveira A, et al. 2003. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscler. Thromb. Vasc. Biol. 23:688-94
73. Wolfort FG, Cetrulo CL, Nevarre DR. 1999. Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use. Plast. Reconstr. Surg. 104:1814-20; discussion 1821-22
74. Rietschel P, Hadigan C, Corcoran C, et al. 2001. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J. Clin. Endocrinol. Metab. 86:504-10
75. Cuneo RC, Judd S, Wallace JD, et al. 1998. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults. J. Clin. Endocrinol. Metab. 83:107-16
76. Wanke C, Gerrior J, Kantaros J, et al. 1999. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 13:2099-103